Using mathematical models to improve immune therapy for bladder cancer
Official title: Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11053601 · Data updated 2026-11-12
This study is exploring a new way to treat bladder cancer by using your own immune cells to fight the disease, and it aims to make the treatment more effective and easier on your body by giving smaller doses directly into the bladder.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | April 1, 2021 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $476,037 |
| NIH project number | 5R01CA259387-05 |
| Project ID | NIH-11053601 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with bladder cancer who are seeking innovative treatment options.
✕Less likely to help
Patients with bladder cancer who are not eligible for immunotherapy or those with advanced metastatic disease may not benefit from this research.
What this research studies
This research investigates a novel approach to treating bladder cancer by utilizing adoptive cell therapy (ACT), where a patient's own immune cells are expanded and activated outside the body before being reinfused. The study aims to optimize this therapy by using mathematical modeling to design and validate treatment protocols that can be administered directly into the bladder, allowing for more frequent and smaller doses of therapy. By integrating pre-clinical mouse models and experimental data, the research seeks to maximize the effectiveness of the treatment while minimizing side effects for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with bladder cancer.
How similar studies have gone: Previous research has shown promise in using adoptive cell therapy for various cancers, indicating potential success for this novel approach in bladder cancer.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Rejniak, Katarzyna Anna — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Rejniak, Katarzyna Anna
Related research
Other NIH-funded projects on the same topics.
-
Cross-species study of immune responses to cancer immunotherapy in dogs and humans with invasive bladder cancer
A study using dogs with naturally occurring invasive bladder cancer to help improve immune checkpoint therapies for people with the same disease.
-
Improving immunotherapy for invasive bladder cancer using insights from dogs and people
This project compares immune responses and immunotherapy effects in people and pet dogs with invasive bladder cancer to find clues that could help more patients benefit from checkpoint drugs.
-
Exploring immune responses in dogs and humans with bladder cancer
This study is looking at how a type of cancer treatment called immune checkpoint inhibitors works for both dogs and humans with bladder cancer, hoping to find ways to make the treatment better for everyone.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.